FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214949510> ?p ?o ?g. }

• W3214949510 endingPage "4227" @default.
• W3214949510 startingPage "4227" @default.
• W3214949510 abstract "Abstract Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening thrombotic microangiopathy (TMA) occurring due to an acquired deficiency in ADAMTS13. Mortality due to iTTP is estimated at 10% with current standard treatment that consists of plasma exchange (PLEX) and corticosteroids. The United States TMA (USTMA) registry incorporates 15 large US referral centers across the nation, and includes patients diagnosed with iTTP between 1985 and 2019. We sought to perform a descriptive analysis on the patients with fatal outcomes attributable to acute iTTP episodes in the registry. Methods: We utilized the USTMA registry (n=771) and analyzed twenty-two baseline patient demographics, presenting symptoms, and laboratory findings. The study cohort included participants with iTTP diagnosis based on the presence of thrombocytopenia (platelet count &lt;100 /µL), microangiopathic hemolyic anemia (hemoglobin less than the lower limit of normal with schistocytes on the peripheral blood smear), and either ADAMTS13 activity &lt;10% or ADAMTS13 activity &lt;20% with an anti-ADAMTS13 inhibitor or antibody. For participants diagnosed before the ADAMTS13 assay was developed (2006), the iTTP diagnosis was based on the clinical course and absence of alternative causes. iTTP exacerbation was defined as clinical disease recurrence within 30 days of PLEX discontinuation, and clinical relapse was defined as disease recurrence after 30 days of last PLEX, as per the international working group definitions 1. Results: A total of 33 patients (4.28%) in the USTMA cohort died during acute iTTP episodes. The patient demographics and initial presenting lab values are summarized in Table 1. Time of death (Figure 1): 22 patients (66.7%) died during the initial iTTP episode, and within 30 days of presentation. 3 patients (9.0%) died during disease exacerbation of the initial episode. 8 patients (24.2%) died due to disease relapse. Median time to death at initial presentation/exacerbation (n=25) = 8 days [IQR: 4-19] Median time to death due to relapse = 1.6 years [IQR: 1.1-5.7] Patient demographics and presenting features (Table 1): Median age = 51 years [IQR: 27.8-60] Sex = 54.5% female, 45.5% male Presence of neurologic symptoms on presentation: 22 (66.7%) Presence of any symptoms on presentation: 32 (97%) Conclusion: Patients with fatal outcomes due to acute iTTP episodes presented with variable symptoms and baseline characteristics. While the vast majority of deaths occurred during the initial acute episode, death also occurred during exacerbation of the initial episode or subsequent disease relapse. Vigilant laboratory and clinical monitoring both after achieving initial remission and during long-term follow-up are necessary, to allow detection of disease exacerbation and relapse, and potentially prevent iTTP-related deaths. 1. Cuker A, Cataland SR, Coppo P, et al. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021;137(14):1855-1861. Figure 1 Figure 1. Disclosures Mazepa: Answering TTP Foundation: Research Funding; Sanofi Aventis: Other. Lim: Hema Biologics: Honoraria; Sanofi Genzyme: Honoraria; Dova Pharmaceuticals: Honoraria." @default.
• W3214949510 created "2021-12-06" @default.
• W3214949510 creator A5009657464 @default.
• W3214949510 creator A5033123441 @default.
• W3214949510 creator A5044794766 @default.
• W3214949510 creator A5047835985 @default.
• W3214949510 creator A5061198124 @default.
• W3214949510 creator A5070606803 @default.
• W3214949510 date "2021-11-05" @default.
• W3214949510 modified "2023-10-14" @default.
• W3214949510 title "A Descriptive Analysis of Immune Thrombotic Thrombocytopenic Purpura (iTTP) Patients with Fatal Outcomes in the U.S. Thrombotic Microangiopathy (USTMA) TTP Registry" @default.
• W3214949510 doi "https://doi.org/10.1182/blood-2021-154292" @default.
• W3214949510 hasPublicationYear "2021" @default.
• W3214949510 type Work @default.
• W3214949510 sameAs 3214949510 @default.
• W3214949510 citedByCount "0" @default.
• W3214949510 crossrefType "journal-article" @default.
• W3214949510 hasAuthorship W3214949510A5009657464 @default.
• W3214949510 hasAuthorship W3214949510A5033123441 @default.
• W3214949510 hasAuthorship W3214949510A5044794766 @default.
• W3214949510 hasAuthorship W3214949510A5047835985 @default.
• W3214949510 hasAuthorship W3214949510A5061198124 @default.
• W3214949510 hasAuthorship W3214949510A5070606803 @default.
• W3214949510 hasBestOaLocation W32149495101 @default.
• W3214949510 hasConcept C126322002 @default.
• W3214949510 hasConcept C134018914 @default.
• W3214949510 hasConcept C141071460 @default.
• W3214949510 hasConcept C187212893 @default.
• W3214949510 hasConcept C2776513394 @default.
• W3214949510 hasConcept C2777014857 @default.
• W3214949510 hasConcept C2777878052 @default.
• W3214949510 hasConcept C2778248108 @default.
• W3214949510 hasConcept C2778585876 @default.
• W3214949510 hasConcept C2778639011 @default.
• W3214949510 hasConcept C2778715236 @default.
• W3214949510 hasConcept C2779134260 @default.
• W3214949510 hasConcept C2780921031 @default.
• W3214949510 hasConcept C2781127562 @default.
• W3214949510 hasConcept C555293320 @default.
• W3214949510 hasConcept C65245452 @default.
• W3214949510 hasConcept C71924100 @default.
• W3214949510 hasConcept C72563966 @default.
• W3214949510 hasConcept C89560881 @default.
• W3214949510 hasConcept C90924648 @default.
• W3214949510 hasConceptScore W3214949510C126322002 @default.
• W3214949510 hasConceptScore W3214949510C134018914 @default.
• W3214949510 hasConceptScore W3214949510C141071460 @default.
• W3214949510 hasConceptScore W3214949510C187212893 @default.
• W3214949510 hasConceptScore W3214949510C2776513394 @default.
• W3214949510 hasConceptScore W3214949510C2777014857 @default.
• W3214949510 hasConceptScore W3214949510C2777878052 @default.
• W3214949510 hasConceptScore W3214949510C2778248108 @default.
• W3214949510 hasConceptScore W3214949510C2778585876 @default.
• W3214949510 hasConceptScore W3214949510C2778639011 @default.
• W3214949510 hasConceptScore W3214949510C2778715236 @default.
• W3214949510 hasConceptScore W3214949510C2779134260 @default.
• W3214949510 hasConceptScore W3214949510C2780921031 @default.
• W3214949510 hasConceptScore W3214949510C2781127562 @default.
• W3214949510 hasConceptScore W3214949510C555293320 @default.
• W3214949510 hasConceptScore W3214949510C65245452 @default.
• W3214949510 hasConceptScore W3214949510C71924100 @default.
• W3214949510 hasConceptScore W3214949510C72563966 @default.
• W3214949510 hasConceptScore W3214949510C89560881 @default.
• W3214949510 hasConceptScore W3214949510C90924648 @default.
• W3214949510 hasIssue "Supplement 1" @default.
• W3214949510 hasLocation W32149495101 @default.
• W3214949510 hasOpenAccess W3214949510 @default.
• W3214949510 hasPrimaryLocation W32149495101 @default.
• W3214949510 hasRelatedWork W1977636062 @default.
• W3214949510 hasRelatedWork W2012585132 @default.
• W3214949510 hasRelatedWork W2124400226 @default.
• W3214949510 hasRelatedWork W2799279069 @default.
• W3214949510 hasRelatedWork W2804249452 @default.
• W3214949510 hasRelatedWork W2891736565 @default.
• W3214949510 hasRelatedWork W3082726724 @default.
• W3214949510 hasRelatedWork W3122465999 @default.
• W3214949510 hasRelatedWork W3210301086 @default.
• W3214949510 hasRelatedWork W3214949510 @default.
• W3214949510 hasVolume "138" @default.
• W3214949510 isParatext "false" @default.
• W3214949510 isRetracted "false" @default.
• W3214949510 magId "3214949510" @default.
• W3214949510 workType "article" @default.